DaxibotulinumtoxinA
- Generic Name
- DaxibotulinumtoxinA
- Brand Names
- Botox, Botox Cosmetic, Daxxify, Dysport, Xeomin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 93384-43-1
- Unique Ingredient Identifier
- E211KPY694
- Background
DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.
DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. DAXI or DAXXIFY, a product of daxibotulinumtoxinA, incorporates RTP004, a proprietary synthetic stabilizing peptide for enhanced product stability.
- Indication
DaxibotulinumtoxinA is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. It is also used for the treatment of cervical dystonia in adult patients.
- Associated Conditions
- Cervical Dystonia, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL)
- Associated Therapies
- -
New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of ...
Galderma announces phase III READY-4 trial data showing long-term safety of RelabotulinumtoxinA for frown lines and crow’s feet, with efficacy and patient satisfaction maintained across multiple treatments. The study met primary and secondary endpoints, with mild or moderate treatment-emergent adverse events reported by 18% of participants. RelabotulinumtoxinA, developed using PEARL™ Technology, is the first ready-to-use liquid neuromodulator optimized for simple volumetric dosing.
Related Clinical Trials:
US FDA approves Allergan's Botox Cosmetic for moderate to severe vertical bands
Allergan Aesthetics, an AbbVie company, announced US FDA approval of Botox Cosmetic for temporary improvement in moderate to severe vertical bands connecting the jaw and neck. This marks the fourth aesthetic indication for Botox Cosmetic, expanding its use beyond facial lines. Clinical studies showed significant improvement in platysma band appearance, with 65% and 62% of patients reporting satisfaction 14 days post-treatment.
AbbVie Botox use expands beyond face (ABBV:NYSE)
FDA approves fourth indication for AbbVie's Botox Cosmetic, expanding its use beyond facial wrinkles.
Allergan’s BOTOX Cosmetic gets FDA approval in jaw-neck bands
Allergan Aesthetics, an AbbVie company, received FDA approval for BOTOX Cosmetic to temporarily improve moderate to severe vertical jaw-neck bands in adults. This marks BOTOX Cosmetic as the first product with four aesthetic indications, now including platysma bands, targeting muscle activity beneath the surface.
Allergan's BOTOX Cosmetic gets FDA approval in jaw-neck bands
Allergan Aesthetics, an AbbVie company, announces U.S. FDA approval of BOTOX Cosmetic for temporary improvement in moderate to severe vertical platysma bands in adults, expanding its aesthetic indications beyond the face.
Botox Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
Allergan Aesthetics announces FDA approval of Botox Cosmetic for temporary improvement in moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults, expanding its aesthetic indications beyond the face.
2024 AMP Top Professionals: Sidney Bennett, Growth Mindset
Sidney Bennett, an aesthetic injector and registered nurse, joined Beyond Wellness in June and plans to help expand its services. She enjoys the beauty industry and provides treatments like facial fillers and PRP. Bennett emphasizes continuous learning and networking, aiming to train other nurse injectors. She looks forward to Beyond Wellness opening a Hillcrest location, offering more convenient services to downtown Little Rock.
Domestic botulinum toxin (Botox) companies are becoming more active in entering and ...
Domestic botulinum toxin companies, including Hugel and Daewoong Pharmaceutical, are expanding into the U.S. market. Hugel aims to launch Retivo in the U.S. this year, targeting a 10% market share within three years. The U.S. Botox market, valued at $4.74 billion, is 30 times larger than Korea's, and AbbVie's dominance is declining. Daewoong's Jubo, already in the U.S., saw sales rise to $202 million. Medytox is also preparing to re-enter the U.S. market.
CGRP Monoclonal Antibodies Not More Effective Than Topiramate or Botox for Treating Migraine
A study by Hema Mistry, PhD, found no evidence that CGRP monoclonal antibodies are more effective than topiramate or Botox for chronic migraine, suggesting they may not be recommended over topiramate without significant price reduction. The review included 11 RCTs testing 6 drugs, showing CGRP antibodies reduced headache days by 2.0-2.5 days/month, with eptinezumab 300 mg and fremanezumab monthly being most effective. Despite higher costs, injected drugs were deemed cost-effective, with topiramate being the least expensive but least effective. Future research priorities include comparing CGRP antibodies and Botox, candesartan vs placebo, and flunarizine vs placebo.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath